Bacteria

Pubic hair: beyond brazilians, more than manscaping

Retrieved on: 
Wednesday, April 10, 2024

So, what about pubic hair?

Key Points: 
  • So, what about pubic hair?
  • Let’s talk about sex
    Much of the effort that goes into shaping or removing pubic hair also shapes and defines sexual identities.
  • While the properties of pheromones are not as well established in humans, there’s speculation that pubic hair plays a significant role.
  • Pubic hair grooming has been associated with an increased risk of genital infections but this has also been refuted.

Infections after surgery are more likely due to bacteria already on your skin than from microbes in the hospital − new research

Retrieved on: 
Wednesday, April 10, 2024

Genetic data from the bacteria causing these infections – think CSI for E. coli – tells another story: Most health care-associated infections are caused by previously harmless bacteria that patients already had on their bodies before they even entered the hospital.

Key Points: 
  • Genetic data from the bacteria causing these infections – think CSI for E. coli – tells another story: Most health care-associated infections are caused by previously harmless bacteria that patients already had on their bodies before they even entered the hospital.
  • We show that many surgical site infections after spinal surgery are caused by microbes that are already on the patient’s skin.

Surgical infections are a persistent problem

  • Among the different types of heath care-associated infections, surgical site infections stand out as particularly problematic.
  • A 2013 study found that surgical site infections contribute the most to the annual costs of hospital-acquired infections, totaling over 33% of the US$9.8 billion spent annually.
  • Still, surgical site infections occur following about 1 in 30 procedures, typically with no explanation.
  • While rates of many other medical complications have shown steady improvement over time, data from the Agency for Healthcare Research and Quality and the Centers for Disease Control and Prevention show that the problem of surgical site infection is not getting better.

BYOB (Bring your own bacteria)

  • Prior studies on surgical site infection have been limited to a single species of bacteria and used older genetic analysis methods.
  • But new technologies have opened the door to studying all types of bacteria and testing their antibiotic resistance genes simultaneously.
  • Over a one-year period, we sampled the bacteria living in the nose, skin and stool of over 200 patients before surgery.
  • In fact, 86% of the bacteria causing infections after spine surgery were genetically matched to bacteria a patient carried before surgery.
  • That number is remarkably close to estimates from earlier studies using older genetic techniques focused on Staphylococcus aureus.
  • They likely acquired these antibiotic-resistant microbes through prior antibiotic exposure, consumer products or routine community contact.

Preventing surgical infections

  • At face value, our results may seem intuitive – surgical wound infections come from bacteria that hang out around that part of the body.
  • If the most likely source of surgical infection – the patient’s microbiome – is known in advance, this presents medical teams with an opportunity to protect against it prior to a scheduled procedure.
  • The fact that most infections don’t actually start with sources in the hospital is probably a testament to the efficacy of these protocols.


Dustin Long receives funding from the National Institutes of Health. Dr Bryson-Cahn receives funding from the Gordon and Berry Moore Foundation and is the co-medical director for Alaska Airlines.

Five Talented Women Scientists from the Global South Win OWSD-Elsevier Foundation Research Prize for Their Work on New Ways to Tackle Water Quality Issue

Retrieved on: 
Thursday, March 21, 2024

The 2024 OWSD-Elsevier Foundation Awards have recognized women-led science from more than 20 low- and middle-income countries since 2013

Key Points: 
  • The prize also acknowledges the scientists’ commitment to leadership, mentoring and engagement within their communities, including the translation of research into actionable insights for stakeholders.
  • We are so proud of them and are sure this prize is just one step on their path to success."
  • By offering this prize, we want to spotlight the important research undertaken by the women who've become inspiring role models for communities most affected by this issue."
  • To find out how the OWSD-Elsevier Foundation Award helps shape our understanding of the global South, read more about the 2023 winners here .

GERMAGIC(TM) PET Hosts "Social Inclusion Charity Run with Pets"

Retrieved on: 
Monday, March 18, 2024

GERMAGIC(TM) PET is the title sponsor of the "Social Inclusion Charity Run with Pets" on 17 March.

Key Points: 
  • GERMAGIC(TM) PET is the title sponsor of the "Social Inclusion Charity Run with Pets" on 17 March.
  • To provide pets with more care and protection, GERMAGIC(TM) PET continuously innovates and utilizes its scientific research technology to develop various green pet health products, thus promoting social inclusion and sustainable development.
  • GERMAGIC(TM) PET products utilize GERMAGIC(TM)'s encapsulation technology and molecular materials to comprehensively support and protect pet health.
  • This certification not only recognizes the quality of GERMAGIC(TM) PET products but also sets higher quality standards for the pet health industry.

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Retrieved on: 
Thursday, March 28, 2024

SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the year ended December 31, 2023 and provided a company update.

Key Points: 
  • In addition, we are excited about the increased attention that women’s health has received more broadly,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience.
  • In December 2023, Daré announced positive topline results from the Phase 1 study evaluating the pharmacokinetics (PK), safety, and exploratory efficacy of DARE-PDM1.
  • Financial Highlights for the Year Ended December 31, 2023 and 2024 Projections
    Cash and cash equivalents: $10.5 million at December 31, 2023.
  • Daré will host a conference call and live webcast today, March 28, 2024, at 4:30 p.m. Eastern Time to review financial results for the year ended December 31, 2023 and to provide a company update.

Kraig Biocraft Laboratories Shares Industry Update on Recombinant Spider Silk from Waste Plastics

Retrieved on: 
Thursday, March 28, 2024

ANN ARBOR, Mich., March 28, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Kraig Labs" or "the Company"), comments on an exciting advancement in spider silk engineering from the Rensselaer Polytechnic Institute ("RPI").

Key Points: 
  • ANN ARBOR, Mich., March 28, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Kraig Labs" or "the Company"), comments on an exciting advancement in spider silk engineering from the Rensselaer Polytechnic Institute ("RPI").
  • Researchers at RPI published a paper in Microbial Cell Factories outlining a new and novel method of creating spider silk protein from waste plastics.
  • Kraig Labs' recombinant spider silk production model utilizes traditional silk production systems involving planting mulberry trees to harvest and feed the leaves to silkworms.
  • The Company's specialized silkworms have been scientifically enhanced through molecular biology to create recombinant spider silk cocoons that are reeled to produce spider silk yarns and fabrics.

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

Retrieved on: 
Tuesday, April 9, 2024

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that enrollment is complete in the placebo-controlled Cohort 2 of its Phase 1b trial of SER-155 in patients who received Allogeneic Hematopoietic Stem Cell Transplantation (Allo HSCT).

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that enrollment is complete in the placebo-controlled Cohort 2 of its Phase 1b trial of SER-155 in patients who received Allogeneic Hematopoietic Stem Cell Transplantation (Allo HSCT).
  • Infections are a leading cause of mortality and morbidity in this immunocompromised patient population.
  • Our pending clinical results could validate the promise of microbiome therapeutics to prevent poor outcomes associated with pathogens in the GI tract.
  • Study Cohort 2, which includes 45 participants, incorporates a randomized, double-blinded placebo-controlled 1:1 design to further evaluate safety and engraftment, as well as clinical outcomes.

Orthobond Secures De Novo Classification Grant for First-in-Class Antibacterial Surface Treatment Applied to a Spinal Device

Retrieved on: 
Monday, April 8, 2024

Orthobond Corporation , a leader in covalently-bound antibacterial surface technologies with broad applications in the medical device industry, announced today that the U.S. Food and Drug Administration (FDA) granted its De Novo marketing request for the use of Ostaguard™, its proprietary antibacterial surface treatment, on a permanent medical device.

Key Points: 
  • Orthobond Corporation , a leader in covalently-bound antibacterial surface technologies with broad applications in the medical device industry, announced today that the U.S. Food and Drug Administration (FDA) granted its De Novo marketing request for the use of Ostaguard™, its proprietary antibacterial surface treatment, on a permanent medical device.
  • Numerous studies have shown between 70-100% of explanted hardware from failed joint implants have some level of contamination from different sources.
  • Orthobond pioneered a method to covalently-bond its antibacterial molecule to the surface of implants.
  • The proprietary surface technology is applied during the manufacturing process prior to packaging and sterilization.

Protein ice cream company wins 2024 Rice Business Plan Competition

Retrieved on: 
Monday, April 8, 2024

HOUSTON, April 8, 2024 /PRNewswire/ -- Ice cream company Protein Pints took home the grand prize at the 2024 Rice Business Plan Competition (RBPC) April 6 as the best student ventures from top universities across the world competed for prizes in front of nearly 350 angel, venture capital and corporate investors and members of the business community.

Key Points: 
  • HOUSTON, April 8, 2024 /PRNewswire/ -- Ice cream company Protein Pints took home the grand prize at the 2024 Rice Business Plan Competition (RBPC) April 6 as the best student ventures from top universities across the world competed for prizes in front of nearly 350 angel, venture capital and corporate investors and members of the business community.
  • The best student ventures from top universities across the world competed in the 2024 Rice Business Plan Competition.
  • Hosted annually by the Rice Alliance for Technology and Entrepreneurship and Rice University's Jones Graduate School of Business , the RBPC is the world's largest and richest student startup competition.
  • Protein Pints is a high-protein, low-sugar, ice cream product designed for people who would benefit from having access to a functional ice cream and/or better tasting and more enjoyable protein options.

Onkos Surgical Announces First FDA De Novo Approval of an Antibacterial Coating for Tumor and Revision Orthopaedic Implants

Retrieved on: 
Monday, April 8, 2024

PARSIPPANY, N.J., April 8, 2024 /PRNewswire/ -- Onkos Surgical, an orthopaedic company founded to address the complex clinical challenges associated with bone loss due to tumor, trauma, and revision surgery, announced that the U.S. Food & Drug Administration (FDA) granted the company a De Novo approval for its novel antibacterial coated implants. Bacterial contamination of a permanent implant may have devastating effects, particularly in orthopedic oncology and revision arthroplasty applications where the patient population is highly vulnerable.

Key Points: 
  • PARSIPPANY, N.J., April 8, 2024 /PRNewswire/ -- Onkos Surgical, an orthopaedic company founded to address the complex clinical challenges associated with bone loss due to tumor, trauma, and revision surgery, announced that the U.S. Food & Drug Administration (FDA) granted the company a De Novo approval for its novel antibacterial coated implants.
  • Bacterial contamination of a permanent implant may have devastating effects, particularly in orthopedic oncology and revision arthroplasty applications where the patient population is highly vulnerable.
  • "Implant contamination is a growing concern to the orthopaedic surgical community," said Steven Gitelis, MD, Onkos Surgical Chief Medical Officer, Rush Medical College, Endowed Professor of Orthopaedic Oncology and Director, Musculoskeletal Oncology at Rush Cancer Center.
  • The Onkos technology is a significant innovation and another option to help reduce local bacterial load on the implant."